The epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) pathways play key and often complementary roles in the pathogenesis of colorectal cancer (CRC). This study explores the clinical and biological effects of combined blockade of these pathways.
T he epidermal growth factor receptor (EGFR) pathway is important in carcinogenesis. It plays key roles in cell proliferation, adhesion, invasion, survival, and angiogenesis. Tumors in which the EGFR pathway is activated include lung cancer, colorectal cancer (CRC), pancreatic cancer, breast cancer, and head and neck cancer. Antibodies and small molecule inhibitors acting on different parts of this pathway have shown effectiveness as antineoplastic agents in these cancers. 1, 2 In CRC, antibodies to EGFR have been used both as a monotherapy and in combination with chemotherapy. Cetuximab, a chimeric neutralizing antibody against the extracellular, ligand-binding domain of the EGFR, was the first EGFR antibody approved by the Food and Drug Administration (FDA) for the treatment of advanced CRC. As a monotherapy, it is associated with a 10% response rate in chemotherapy refractory CRC. Interestingly, in patients who had progressed on irinotecan-based chemotherapy, the combination of cetuximab and irinotecan yielded a 23% response rate whereas single agent cetuximab only had an 11% response rate, suggesting that cetuximab may overcome irinotecan resistance in some tumors. 3 The cyclooxygenase (COX) pathway is another important pathway in carcinogenesis. COXs convert arachidonic acid to prostaglandins, and prostaglandins are involved in vasoconstriction, vasodilation, platelet aggregation, and immunomodulation. There are 2 isoforms of COX, COX-1 and COX-2. COX-2 is the isoform whose up-regulation is most commonly associated with carcinogenesis. 4 Preclinical data showed that up-regulation of COX-2 in tumor cells result in increased Prostaglandin E2 (PGE 2 ) production and increased tumor invasiveness. 5 The increased PGE 2 production can then lead to increased production of interleukin-6, interleukin-10, and increased Bcl-2, all of which can favor tumor growth and dissemination. It can also promote proangiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and transforming growth factor beta 1 (TGF-b1). 6 COX-2 is overexpressed in many tumor types, including colon, lung, breast, liver, head and neck, pancreas, esophagus, and prostate. Up-regulation of COX-2 has been observed in adenomatous colorectal polyps 7 and in Barrett esophagus, 8 2 precancerous states.
Celecoxib, a selective oral COX-2 inhibitor, at a dose of 200 mg BID, is used in patients with arthritis. This dose level is well tolerated. At a higher dose of 400 mg BID, it has been shown to prevent/reduce colon polyps in individuals with familial adenomatous polyposis. 9 COX-2 overexpression may induce EGFR expression, which can enhance tumor growth. 10 The human colon cancer cell line COLO 320DM transfected with COX-1 or COX-2 had growth rates 2-fold faster than mock-transfected cells, increased DNA synthesis, and increased expression of EGFR. The addition of indomethacin, a COX-1 and COX-2 inhibitor, suppressed the stimulated growth, the increased DNA synthesis, and the induction of EGFR in the COX-1 Àtransfected and COX-2 À transfected cells.
Therefore, this study sought to explore these findings further in the clinical setting by inhibiting these 2 complementary pathways in patients with metastatic CRC with the combination of cetuximab and celecoxib. Laboratory correlative studies were incorporated to evaluate the biological effect of the combination and to determine whether the targets were sufficiently inhibited. TGF-a, the principal ligand for EGFR, is overexpressed in a variety of tumor types. Pretreatment and posttreatment serum samples were collected for these assays. Monoclonal antibody blockade of EGFR may result in increased levels of soluble TGF-a. 11, 12 Measurement of COX-2 activity in vivo is difficult given the variability in tumor tissue availability. However, indirect assessment of COX-2 activity may be possible through measurement of endogenous prostaglandin production as assessed by the measurement of their urinary metabolites. PGE 2 -11-a-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxy-prostanoic acid (PGE-M) is the principal urinary metabolite of PGE 2 . 13 As COX-2 is not constitutively expressed in normal tissues, in patients with CRC, the major source of urinary PGE-M presumably originates within the tumor as a result of COX-2 À induced PGE 2 production. Changes in urine PGE-M levels in response to a COX-2 inhibitor may serve as a surrogate marker of COX-2 activity within the tumor itself. Pretreatment and posttreatment urine PGE-M levels were assayed to assess the adequacy of COX-2 inhibition. These correlative studies were designed to determine the feasibility of using these biomarkers as predictive markers of efficacy in subsequent trials.
PATIENTS AND METHODS

Xenograft Experiments
We previously identified that a human CRC cell line, HCA-7, expresses COX-2. 14 These cells retain the capacity to form a uniform polarizing monolayer when cultured on Transwell filters. HCA-7 cells (2Â 10 7 ) were injected subcutaneously into nu/nu mice. When tumors reached approximately 150 mm 3 , the mice received EKI-785 (25 mg/kg, 50 mg/kg thrice a week, intraperitoneally), rofecoxib (5 mg/kg, 10 mg/kg daily gavage), or both EKI-785 (50 mg/kg) and rofecoxib (5 mg/kg) for 1 month. EKI-785 was supplied by Wyeth-Ayerst (Madison, NJ) and rofecoxib was supplied by Merck (Rahway, NJ). Tumor volumes were measured thrice a week. There were 10 mice per group. Control for rofecoxib was methylcellulose by gavage, and control for EKI-785 was dimethyl sulfoxide (DMSO) by intraperitoneal injection.
Clinical Trial
This was a phase II open label single institution study to evaluate the efficacy of cetuximab in combination with celecoxib in CRC. Given that both agents were well tolerated and had nonoverlapping toxicities, the doses chosen for the study were full doses of both agents, that is, cetuximab 400 mg intravenous (IV) loading dose followed by 250 mg IV weekly and celecoxib 200 mg per oral BID. There was a planned toxicity evaluation after the first 6 patients with dose deescalation if the combination was not well tolerated.
Eligibility
Patients were required to have histologically confirmed metastatic or unresectable CRC for which standard curative or palliative measures do not exist or are no longer effective apart from EGFR antibody therapy. They had to have progressed after Z1 chemotherapy regimen for advanced disease. Earlier, therapy with agents targeting the EGFR pathway was not allowed. Patients had to be Z18 years old, have an ECOG performance status r2, and have measurable disease (at least 1 lesion with longest diameter Z20 mm with conventional techniques or Z10 mm with spiral computed tomography scan) with a life expectancy of >3 months. They had to have adequate organ and marrow function, defined as absolute neutrophil count Z1500/mL, platelets Z100,000/mL, normal total bilirubin, aspartate aminotransaminase (serum glutamate oxaloacetate transaminase)/alanine aminotransaminase (serum glutamate pyruvate transaminase) r2.5Â institutional upper limit of normal or r5 Â normal if liver metastases are present, normal creatinine or estimated creatinine clearance Z60 mL/ min/1.73 m 2 by Cockroft-Gault calculation for patients with creatinine levels above institutional normal. Patients had to agree to use adequate contraception. Patients were required to understand and give written informed consent. Ineligibility criteria included patients with chemotherapy or radiotherapy within 4 weeks (6 wk for nitrosourea or mitomycin C) before entering the study or patients who had not recovered from adverse events of earlier therapy. Patients receiving investigational agents or patients with brain metastases were ineligible. Patients who had previously had a severe infusion reaction to a monoclonal antibody were ineligible. Apart from a daily 81 mg aspirin, patients were required to be off all other selective or nonselective COX-2 inhibitors for a minimum of 2 weeks before study entry. Patients with serum calcium >12 mg/dL were ineligible. Patients were not allowed to have had major surgery within 4 weeks of study entry or minor surgery within 1 week of study entry. Significant traumatic injury occurring within 28 days of treatment initiation was not allowed. Patients with gastrointestinal tract disease resulting in inability to take oral medication or a requirement for IV alimentation or earlier surgical procedures affecting absorption or active peptic ulcer disease were ineligible. Patients with uncontrolled intercurrent illness or psychiatric illnesses/social situations that would limit compliance with study requirements were also ineligible. Pregnant women or individuals with HIV were ineligible.
Treatment
The study was conducted at Vanderbilt University Medical Center in Nashville, TN. Patients were accrued from May 2005 to October 2006. Cetuximab was given weekly. During week 1, patients received cetuximab at 400 mg/m 2 over 2 hours. For the initial cetuximab dose, patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) intravenously given 30 to 60 minutes before the first dose of cetuximab. Additional premedication for the initial treatment and for subsequent treatments was at the investigator's discretion. Subsequent doses were administered at 250 mg/m 2 over 1 hour. Subsequent doses of cetuximab could be dose reduced and/or dose delayed secondary to toxicity. Patients were instructed to take celecoxib 200 mg orally twice a day. Cetuximab was supplied free of charge by Bristol-Myers Squibb (Princeton, NJ). Celecoxib was supplied free of charge by Pfizer, Inc (New York, NY).
Patients were closely monitored during the cetuximab infusion and observed for 1 hour afterward for any signs of anaphylaxis. If grade 3 or greater infusion reaction occurred, patients were removed from study. All toxicities were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 3.0.
Serum and urine samples were obtained before the start of therapy, 1 week after starting therapy, and at the beginning of each new cycle. On the days of serum sampling, celecoxib was taken before or during the cetuximab infusion.
Urinary PGE-M PGE 2 production was quantified by measuring the major metabolite of PGE-M by mass spectrometry as previously described. 15 For these analyses, stable isotope dilution methodology was employed using chemically synthesized ( 2 H 7 ) PGE-M as a standard. For the quantification of this compound in human urine, the following approach was used. Urine (1 mL) and À20 ng ( 2 H 7 ) PGE-M was acidified with HCl (1 M) to pH3 and 0.5 mL of 0-methylhydroxylamine HCl (40 mg) in acetate buffer (1.5 M, pH 5) was added to form methoxamine. The prostanoid derivative was extracted twice as the carboxylic acid at pH 2.5 (HCl, 1 M) with 3 mL ethyl acetate/hexane (70:30 vol/vol). After evaporation of the solvent, acetonitrile (30 mL), 35% pentafluorobenzyl bromide in acetonitrile (15 mL) and N-ethyldiisopropylamine (10 mL) were added. The mixture was allowed to react at 401C for 25 minutes. The dry sample was then purified by thin layer chromatography (TLC) in a solvent system of ethyl acetate/ hexane 90:10 vol/vol. PGE-M has an Rf of 0.63. A broad zone (Rf = 0.53-0.70) was scraped from the TLC and eluted with ethyl acetate. The solvent was evaporated and the prostanoid was derived from N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) (25 mL) and dimethyl formamide (10 mL) after 1 hour. The sample was dried and resuspended in 10 mL undecane for mass spectrometric analysis. For mass spectrometric analysis, a Finnegan MAT TSQ45 gas chromatograph/ mass spectrometer was employed. Gas chromatography was performed using a DB1701 capillary column (30 m, 0.25 mm internal diameter, 0.25 mm film thickness). The column temperature was programmed from 1901C to 3001C at 201C per minute. The major ion generated in the NICI mass spectrum of the PFB ester, O-methyloxime, and TMS ether derivative of PGE-M was m/z 637 and the corresponding ion generated by the ( 2 H 7 ) PGE-M standard was m/z 644. Levels of endogenous PGE-M in a biological sample were calculated from the ratio of intensities of the ions m/z 637 to m/z 644.
Methods for Analyzing Serum TGF-a
Methods used for analyzing serum for the ligand TGF-a were previously reported. 12 Methods for Detection of Cetuximab À Cross-reacting IgE The cetuximab À cross-reacting IgE in the pre-cetuximab treatment serum samples were detected as a part of a previously published study. 16 
Tumor Evaluation
Response to therapy was evaluated with serial CT scans every 8 weeks ±1 week. RECIST criteria 17 were used to determine response to therapy. Complete response or partial response (PR) was confirmed with repeat imaging obtained at least 4 weeks later.
Statistical Methods
The t test statistic was used to examine mean TGF-a and PGE-M differences between the response groups at the first treatment cycle. In addition, the average group differences between the first and the second treatment cycle were examined by way of repeated measures analysis of variance. Differences in survival and time to progression curves were tested using the log-rank test statistic.
RESULTS
Tumor Xenografts
We previously showed that administration of TGF-a to the basolateral compartment of polarized HCA-7 cells, a human CRC cell line, results in increased expression of COX-2 and the release of eicosanoids, including PGE 2 , into the basolateral medium. 14 More recently, we have reported that combined blockade of cell surface cleavage of TGF-a (TACE inhibitor), EGFR ligand uptake (cetuximab), and EGFR tyrosine kinase (EKI-785, an irreversible EGFR TKI) results in cooperative growth inhibition of HCA-7 cells in vitro. 2 In these studies, EKI-785 was the most potent single agent. This led to in vivo proofof-principle experiments in HCA-7 nude mouse xenografts in which we combined EKI-785 with rofecoxib, a COX-2 inhibitor. HCA-7 cells were injected subcutaneously into nude mice and allowed to grow to approximately 150 mm 3 . The mice were then treated with EKI-785 alone, rofecoxib alone, or the combination of rofecoxib and EKI-785. Figure 1A illustrates that rofecoxib and EKI-785 as single agents resulted in concentrationdependent tumor growth inhibition. In Figure 1B , the combination of rofecoxib and EKI-785 resulted in marked growth inhibition. These data suggest that inhibition of both COX-2 and EGFR can result in cooperative growth inhibition. However, gefitinib, another EGFR TKI, exhibited no clinical activity in patients with advanced CRC. 18 This led us to conduct the present trial with cetuximab and celebrex.
Patients
Seventeen patients were enrolled from May 2005 to October 2006. Patient demographics are listed in Table 1 . Thirteen patients were evaluable for response. Four patients went off study for toxicity or complications. Three of the patients were removed for grade 3 infusion reaction with the first dose of cetuximab. One patient was removed for grade 2 conjunctivitis. No patient died while on treatment. Table 2 lists the grade 3 and 4 toxicities seen in patients on this study. Treatment was well tolerated, and no unexpected toxicities were seen with the exception of a high rate of grade 3 hypersensitivity reactions in this small patient population. The only grade 3 or 4 toxicities attributed to protocol therapy were hypersensitivity reactions and dermatological toxicities. One patient experienced urinary hemorrhage but this was secondary to disease progression. One patient experienced grade 4 neurological toxicity that was due to the development of brain metastases. One patient reported grade 3 sensory neuropathy but this was present before the start of therapy and did not worsen on therapy. An episode of grade 3 constipation was felt to be unrelated to therapy as it was present at the start of therapy. One patient had grade 3 urinary retention that was present before the start of protocol therapy and did not change on therapy.
Treatment Toxicity
As mentioned, the rate of grade 3 hypersensitivity reactions (3/17 patients, 17.6%) was high for this population compared with the rate reported in the package insert (3%). 19 It has previously been reported that hypersensitivity reactions to cetuximab are secondary to a preexisting IgE antibody against cetuximab. 15 The patients in this study made up part of the data set for that published study and the IgE values are listed in Table 3 . The limit of detection of the assay is 0.35 IU/mL. All patients with grade 3 hypersensitivity reactions had detectable IgE antibodies against cetuximab. Patient 9 had a minimally detected IgE antibody level of 0.37 IU/mL. He had a minimal reaction manifested as pruritis affecting the palms and feet and red hands that was judged by the treating physician to not represent a true hypersensitivity reaction. The other 3 patients with detectable IgE levels had clear grade 3 hypersensitivity reactions and were not rechallenged.
Clinical Efficacy
Of the 13 evaluable patients, 2 (15.4%) had confirmed PR, 4 (30.8%) had stable disease (SD), and 7 (53.8%) had progressive disease (PD).
The median progression-free survival (PFS) for all patients (except for the 3 with grade 3 infusion reactions and 1 with toxicity) was 55 days (95% confidence interval (CI), 45-112; range, 10-295 d]. For patients with SD or PR, the median PFS was 138 days (95% CI, 112-167). For patients with PD, the median PFS was 47 days (95% CI, 28-55). As shown in Figure 2 there was a statistically significant difference between the responders and PD survival curves (P = 0.0003). There was no statistically significant difference in survival times between the responder and PD groups (Fig. 3) .
The longest surviving patient in the study progressed after 2 cycles. He was subsequently treated with irinotecan and cetuximab for 9 months before progression. In fact, he had previously progressed on irinotecan as well. He eventually passed away 22 months after he enrolled in the study.
Biologic Correlative Studies
The objective of the biologic correlative studies was to determine whether the combination of cetuximab and celecoxib elicited any change in the EGFR or COX-2 pathway. Table 4 describes the distributions and P values for the urinary PGE-M and serum TGF-a levels for 2 treatment cycles; there were no statistically significant differences between the responder and progression groups. Additionally, there were no statistically significant difference in TGF-a or PGE-M between cycles in either the responder group (P = 0.0524) or the progressive group (P = 0.0609). There were no statistically 
DISCUSSION
The EGFR and COX pathways are targets for pharmacological therapy. Several EGFR inhibitors including small molecule tyrosine kinase inhibitors such as erlotinib and monoclonal antibodies such as cetuximab and panitumumab have been approved by the FDA for cancer therapy. Although monoclonal antibodies have shown single agent efficacy in CRC, 2,20 the small molecule inhibitors are ineffective in this malignancy. 17 Blockade of the COX pathway has proven effective in decreasing the incidence of precancerous polyps in patients with familial adenomatous polyposis. However, studies in CRC have yet to show that blockade of this pathway is effective in controlling malignancy. COX-2 inhibition does not seem to add to the benefit of chemotherapy in metastatic CRC. [21] [22] [23] [24] In fact, preclinical data suggests that it may attenuate the effect on 5-fluorouracil-induced apoptosis in colon cancer cell lines. 25 Because COX-2 overexpression can lead to EGFR expression, we hypothesized that inhibition of both pathways may lead to more effective inhibition of tumor growth than either of them alone. Unfortunately, the response rates in this study did not support this hypothesis and the study was terminated early given the lack of sufficiently promising clinical activity for this drug combination. The RR and PFS were similar to that reported for single agent cetuximab. 3 Not surprisingly, the patients who had SD or PR had improved PFS compared with the patients with PD. What is unexpected is that there was no statistically significant difference in survival between the patients with SD or PR and the patients with PD. Equally interesting is the fact that the longest surviving patient in this study had PD on an earlier irinotecan regimen and on this regimen of cetuximab and celecoxib, but he subsequently had a prolonged period of 9 months of SD with the combination of cetuximab and irinotecan. Although it had previously been speculated that cetuximab may reverse irinotecan resistance, it has not been reported that cetuximab and irinotecan can control disease in patients who had previously progressed on both of these drugs separately.
No unexpected toxicities were seen with the combination. However, there was an unexpectedly high rate of hypersensitivity reactions seen with the first infusion of cetuximab. Although the rate of severe hypersensitivity reactions seen in this study (17.6%) is higher than the previously reported rates of 1% to 3% in other large studies, it is similar to the rate reported for the region of the United States where this study was conducted. 26 As previously reported, this hypersensitivity reaction seems to be secondary to a preexisting IgE antibody in these patients, and the prevalence of this IgE antibody parallels the hypersensitivity rate seen. 15 In this small patient sample, the response rates seen were similar to those previously reported for single agent cetuximab. Given the lack of statistically significant differences in TGF-a or PGE-M between cycles, it is possible that the lack of clinical synergy between cetuximab and celecoxib may be secondary to dosing at levels too low to achieve significant effective systemic biological blockade of the pathways. It may be that we need more potent EGFR and/or COX 2 inhibitors to demonstrate a synergistic effect with the combination in a clinical setting. 
